PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 2026Japanese Journal of Clinical Oncology0 citations

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

View Full Paper
HIHiroki IshiharaKNKoichi NishimuraYNYuki Nemoto

Key Points

  • The study aims to evaluate the effectiveness and safety of third-line therapy after prior treatments in advanced renal cell carcinoma.
  • Analyzed real-world patient outcomes following third-line treatment.
  • Investigated the sequence of immune checkpoint inhibitors and VEGFR-TKIs.
  • Assessed toxicity and clinical effectiveness of the treatments.
  • Third-line therapy demonstrated feasibility with effective clinical outcomes.
  • Toxicity levels were manageable among treated patients.
  • Overall treatment strategy showed promise for advanced RCC management.

Abstract

Third-line systemic therapy following ICI combinations and sequential VEGFR-TKIs shows feasible clinical effectiveness and manageable toxicity in real-world patients with advanced RCC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ishihara et al. (2026) studied this question.

synapsesocial.com/papers/69a7cce8d48f933b5eed8cb5https://doi.org/10.1093/jjco/hyag037
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and <scp>VEGFR</scp> ‐ <scp>TKIs</scp> in Real‐World Patients With Advanced Renal Cell Carcinoma2026 · 1 citations
  2. 2Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study2024 · 1 citations
  3. 3Second-line TKI therapy following first-line immune checkpoint inhibitor combinations in metastatic RCC: A systematic review and meta-analysis of safety outcomes.2026
  4. 4Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study2026
  5. 5Preoperative VEGFR‐TKI Plus ICI Therapy Facilitates 3D‐Guided Cytoreductive Nephron‐Sparing Surgical Feasibility and Immune Remodeling in Advanced Renal Cell Carcinoma2025